Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 18/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933174 | 0.86 | SLC9A1 (0.51) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| SCHEMBL402837 | 0.85 | KMO (0.53) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| SCHEMBL400977 | 0.84 | SLC9A1 (0.56) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| SCHEMBL1918275 | 0.81 | RBP4 (0.58) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| SCHEMBL1809088 | 0.80 | RBP4 (0.57) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| SCHEMBL31188362 | 0.80 | SLC9A1 (0.50) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| SCHEMBL3912829 | 0.78 | RBP4 (0.58) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| SCHEMBL17134229 | 0.78 | SLC9A1 (0.55) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| SCHEMBL30439790 | 0.78 | SLC9A1 (0.55) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 | |
| Hydrochloric Acid SCHEMBL8506230 | 0.78 | SLC9A1 (0.74) | SLC9A1ADRA1DHTR2ASLC6A3SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4116294-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-01-11 | — | — | EP | disclosed |
| WO-2011005290-A1 | DISUBSTITUTED OXADIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | AZI2, GABBR2, CNDP2 | SLC9A1 636/4885ADRA1D 2583/4885HTR2A 1352/4885 |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | AZI2, GABBR2, CNDP2 | SLC9A1 636/4885ADRA1D 2583/4885HTR2A 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.